Two new studies presented at AHA 2025 shed light on post-ablation strategies for atrial fibrillation (AFib). The DARE-AF trial found that a three-month course of dapagliflozin failed to prevent early AFib recurrence in patients without current…
DARE-AF and META-AF: Mixed Outcomes For Drug Strategies Following AFib Ablation
